GlassScriptPhysician profile
Jacolin A Shifrar
NPI 1134261209
$2,207.89
in general payments reported to CMS, 2019-2025
24 companies · $154 in 2025
The $154 reported for 2025 was more than what a typical Advanced Practice Midwife provider received nationally (typical 2025 total: $70.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $569 · 2022: $643 · 2023: $276 · 2024: $566 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $977 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $976.81 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $492.51 | 2021-2024 | |
| Amgen INC. | $293.19 | 2022-2025 | Evenity |
| Hologic Sales and Service, LLC | $264.37 | 2022-2025 | Aptima, Thinprep 2000 Processor, Novasure |
| Organon LLC | $166.25 | 2021-2024 | Nexplanon |
| Exeltis, USA INC. | $141.42 | 2021-2025 | Slynd, Twirla |
| Astellas Pharma US INC | $113.02 | 2021-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $101.61 | 2021-2023 | |
| Evofem Biosciences, INC. | $90.80 | 2021-2022 | |
| Abbott Laboratories | $89.42 | 2022 | |
| Mayne Pharma Commercial LLC | $62.19 | 2021-2022 | |
| Pfizer INC. | $48.60 | 2023 | |
| Daiichi Sankyo INC. | $40.17 | 2021 | |
| Avion Pharmaceuticals | $39.95 | 2021-2022 | |
| Becton, Dickinson and Company | $38.14 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $36.04 | 2021-2023 | Gardasil 9 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $33.50 | 2024 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $25.29 | 2021 | |
| Shield Therapeutics INC | $20.69 | 2024 | |
| Roche Diagnostics Corporation | $20.58 | 2021 | |
| Nestle Healthcare Nutrition INC. | $20.45 | 2021 | |
| Novo Nordisk INC | $19.49 | 2024 | |
| Idorsia Pharmaceuticals US INC | $18.80 | 2022 | |
| Coloplast Corp | $15.83 | 2022 | |
| Scynexis, INC. | $15.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacolin Shifrar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.